Skip to main content
SpringerLink
Log in

In Vitro Activity of Tigecycline Against Acinetobacter baumannii: Global Epidemiology and Resistance Mechanisms

  • Chapter
  • First Online:
Advances in Microbiology, Infectious Diseases and Public Health

Part of the book series: Advances in Experimental Medicine and Biology ((AMIDPH,volume 897))

Abstract

Acinetobacter baumannii is a pathogen of increasing concern, commonly causing outbreaks in the hospital environment. Of particular concern, A. baumannii strains exhibiting resistance to carbapenems, which were previously considered the treatment of choice for infected patients, have dramatically increased worldwide, leaving a few antibacterial choices. Tigecycline, a broad-spectrum modified minocycline derivative, isconsidered as a last resort drug against multidrug-resistant A. baumannii. Though, resistance to tigecycline has emerged and is growing notably following increasing tigecycline usage. Comparative evaluation of the tigecycline resistance rates reported worldwide is challenging due to the absence of official interpretative criteria for in vitro susceptibility testing and the discrepancies among the different susceptibility methodologies used, with broth microdilution being considered the reference method. Tigecycline resistance is mainly associated with resistance-nodulation-cell division (RND)-type transporters, mainly the AdeABC, AdeFGH and AdeIJK efflux pumps, but other resistance mechanisms have also been implicated. Tigecycline is still an attractive choice for A. baumannii, but further investigations are warranted so that treatment of MDR Α. baumannii could be guided by validated in vitro data.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Al-Sweih NA, Al-Hubail MA, Rotimi VO (2011) Emergence of tigecycline and colistin resistance in Acinetobacter species isolated from patients in Kuwait hospitals. J Chemother 23(1):13–16. doi:10.1179/joc.2011.23.1.13

    Article  CAS  PubMed  Google Scholar 

  • Ahmed NH, Baba K, Clay C, Lekalakala R, Hoosen AA (2012) In vitro activity of tigecycline against clinical isolates of carbapenem resistant Acinetobacter baumannii complex in Pretoria, South Africa. BMC Res Notes 3(5):215. doi:10.1186/1756-0500-5-215

  • Amin IM, Richmond GE, Sen P, Koh TH, Piddock LJ, Chua KL (2013) A method for generating marker-less gene deletions in multidrug-resistant Acinetobacter baumannii. BMC Microbiol 13:158. doi:10.1186/1471-2180-13-158

    Article  PubMed  PubMed Central  Google Scholar 

  • Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E (2008) Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 46(4):567–570. doi:10.1086/526775

    Article  PubMed  Google Scholar 

  • Araj GF, Ibrahim GY (2008) Tigecycline in vitro activity against commonly encountered multidrug-resistant gram-negative pathogens in a Middle Eastern country. Diagn Microbiol Infect Dis 62(4):411–415. doi:10.1016/j.diagmicrobio.2008.08.011

    Article  CAS  PubMed  Google Scholar 

  • Baadani AM, Thawadi SI, El-Khizzi NA, Omrani AS (2013) Prevalence of colistin and tigecycline resistance in Acinetobacter baumannii clinical isolates from 2 hospitals in Riyadh Region over a 2-year period. Saudi Med J 34(3):248–253. PMID: 23475088

    Google Scholar 

  • Balode A, Punda-Polic V, Dowzicky MJ (2013) Antimicrobial susceptibility of gram-negative and gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004–2010. Int J Antimicrob Agents 41(6):527–535. doi:10.1016/j.ijantimicag.2013.02.022

    Article  CAS  PubMed  Google Scholar 

  • Behera B, Das A, Mathur P, Kapil A, Gadepalli R, Dhawan B (2009) Tigecycline susceptibility report from an Indian tertiary care hospital. Indian J Med Res 129(4):446–450. PMID: 19535842

    Google Scholar 

  • Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48(1):1–12. doi:10.1086/595011

    Article  PubMed  Google Scholar 

  • Bradford PA, Petersen PJ, Young M, Jones CH, Tischler M, O’Connell J (2005) Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob Agents Chemother 49(9):3903–3909. doi:10.1128/AAC.49.9.3903-3909.2005

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bratu S, Landman D, Martin DA, Georgescu C, Quale J (2008) Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of Acinetobacter baumannii endemic to New York City. Antimicrob Agents Chemother 52(9):2999–3005. doi:10.1128/AAC.01684-07

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Brink AJ, Bizos D, Boffard KD, Feldman C, Grolman DC, Pretorius J, Richards GA, Senekal M, Steyn E, Welkovic N, Association of Surgeons of South A, Critical Care Society of Southern A, Federation of Infectious Diseases Societies of Southern A, South African Thoracic S, Trauma Society of South A (2010) Guideline: appropriate use of tigecycline. S Afr Med J = Suid-Afrikaanse tydskrif vir geneeskunde 100(6 Pt 2):388–394

    Google Scholar 

  • BSAC (2015) Susceptibility testing method. Breakpoint tables version 14 Jan 2015. http://bsac.org.uk/susceptibility/methodologylatestversion/. Accessed 10 Apr 2015

  • Buccoliero G, Morelli E, Lonero G, Romanelli C, Resta F, Pisconti S (2012) Rapid spread of multiresistant Acinetobacter baumannii isolates in intensive care units (ICUs) and in vitro activity of colistin and tigecycline. Infez Med 20(4):296–298

    PubMed  Google Scholar 

  • Canigia LF, Bantar C (2008) Susceptibility testing of tigecycline against Acinetobacter spp. by disc diffusion method: withdrawing a therapeutic option by varying the Mueller-Hinton agar? J Antimicrob Chemother 62(6):1463–1464. doi:10.1093/jac/dkn389

    Article  CAS  PubMed  Google Scholar 

  • Capone A, D’Arezzo S, Visca P, Petrosillo N, Gruppo Romano Acinetobacter b (2008) In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 62(2):422–423. doi:10.1093/jac/dkn172

    Article  CAS  PubMed  Google Scholar 

  • Casal M, Rodriguez F, Johnson B, Garduno E, Tubau F, de Lejarazu RO, Tenorio A, Gimenez MJ, Bartolome R, Garcia-Rey C, Aguilar L, Garcia-Escribano N (2009) Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible Acinetobacter spp. J Antimicrob Chemother 64(1):69–72. doi:10.1093/jac/dkp169

    Article  CAS  PubMed  Google Scholar 

  • Cattoir V, Dowzicky MJ (2014) A longitudinal assessment of antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in France between 2004 and 2012. Antimicrob Resist Infect Control 3(1):36. doi:10.1186/2047-2994-3-36. eCollection 2014.

  • Chan MC, Chiu SK, Hsueh PR, Wang NC, Wang CC, Fang CT (2014) Risk factors for healthcare-associated extensively drug-resistant Acinetobacter baumannii infections: a case-control study. PLoS One 9(1):e85973. doi:10.1371/journal.pone.0085973

    Article  PubMed  PubMed Central  Google Scholar 

  • Chang KC, Lin MF, Lin NT, Wu WJ, Kuo HY, Lin TY, Yang TL, Chen YC, Liou ML (2012) Clonal spread of multidrug-resistant Acinetobacter baumannii in eastern Taiwan. J Microbiol Immunol Infect = Wei mian yu gan ran za zhi 45(1):37–42. doi:10.1016/j.jmii.2011.09.019

  • Chen Q, Li X, Zhou H, Jiang Y, Chen Y, Hua X, Yu Y (2014) Decreased susceptibility to tigecycline in Acinetobacter baumannii mediated by a mutation in trm encoding SAM-dependent methyltransferase. J Antimicrob Chemother 69(1):72–76. doi:10.1093/jac/dkt319

    Article  CAS  PubMed  Google Scholar 

  • Chuang YC, Sheng WH, Li SY, Lin YC, Wang JT, Chen YC, Chang SC (2011) Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with acinetobacter bacteremia. Clin Infect Dis 52(3):352–360. doi:10.1093/cid/ciq154

    Article  PubMed  Google Scholar 

  • Chuang YC, Cheng CY, Sheng WH, Sun HY, Wang JT, Chen YC, Chang SC (2014) Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis. BMC Infect Dis 14:102. doi:10.1186/1471-2334-14-102

    Article  PubMed  PubMed Central  Google Scholar 

  • Coyne S, Guigon G, Courvalin P, Perichon B (2010a) Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray. Antimicrob Agents Chemother 54(1):333–340. doi:10.1128/AAC.01037-09

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Coyne S, Rosenfeld N, Lambert T, Courvalin P, Perichon B (2010b) Overexpression of resistance-nodulation-cell division pump AdeFGH confers multidrug resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 54(10):4389–4393. doi:10.1128/AAC.00155-10

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Coyne S, Courvalin P, Perichon B (2011) Efflux-mediated antibiotic resistance in Acinetobacter spp. Antimicrob Agents Chemother 55(3):947–953. doi:10.1128/AAC.01388-10

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Damier-Piolle L, Magnet S, Bremont S, Lambert T, Courvalin P (2008) AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii. Antimicrob Agents Chemother 52(2):557–562. doi:10.1128/AAC.00732-07

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Deng M, Zhu MH, Li JJ, Bi S, Sheng ZK, Hu FS, Zhang JJ, Chen W, Xue XW, Sheng JF, Li LJ (2014) Molecular epidemiology and mechanisms of tigecycline resistance in clinical isolates of Acinetobacter baumannii from a Chinese university hospital. Antimicrob Agents Chemother 58(1):297–303. doi:10.1128/AAC.01727-13

    Article  PubMed  PubMed Central  Google Scholar 

  • Denys GA, Callister SM, Dowzicky MJ (2013) Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.). Ann Clin Microbiol Antimicrob 12:24. doi:10.1186/1476-0711-12-24

    Article  PubMed  PubMed Central  Google Scholar 

  • Dizbay M, Altuncekic A, Sezer BE, Ozdemir K, Arman D (2008) Colistin and tigecycline susceptibility among multidrug-resistant Acinetobacter baumannii isolated from ventilator-associated pneumonia. Int J Antimicrob Agents 32(1):29–32. doi:10.1016/j.ijantimicag.2008.02.016

    Article  CAS  PubMed  Google Scholar 

  • Doi Y, Murray GL, Peleg AY (2015) Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options. Semin Respir Crit Care Med 36(1):85–98. doi:10.1055/s-0034-1398388

    Article  PubMed  PubMed Central  Google Scholar 

  • ECDC (2013) Antimicrobial resistance surveillance in Europe. Annual report of the European Antimicrobial Resistance Surveillance network. Stockholm: ECDC

    Google Scholar 

  • Espinal P, Seifert H, Dijkshoorn L, Vila J, Roca I (2012) Rapid and accurate identification of genomic species from the Acinetobacter baumannii (Ab) group by MALDI-TOF MS. Clin Microbiol Infect 18(11):1097–1103. doi:10.1111/j.1469-0691.2011.03696.x

    Article  CAS  PubMed  Google Scholar 

  • Farrell DJ, Turnidge JD, Bell J, Sader HS, Jones RN (2010) The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008). J Infect 60(6):440–451. doi:10.1016/j.jinf.2010.03.024

    Article  PubMed  Google Scholar 

  • FDA (2013) Tygacil (tigecycline): drug safety communication – increased risk of death. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm370170.htm. Accessed 10 Apr 2015

  • Fernandez-Mazarrasa C, Mazarrasa O, Calvo J, del Arco A, Martinez-Martinez L (2009) High concentrations of manganese in Mueller-Hinton agar increase MICs of tigecycline determined by Etest. J Clin Microbiol 47(3):827–829. doi:10.1128/JCM.02464-08

    Article  PubMed  PubMed Central  Google Scholar 

  • Fluit AC, Florijn A, Verhoef J, Milatovic D (2005) Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline. Antimicrob Agents Chemother 49(4):1636–1638. doi:10.1128/AAC.49.4.1636-1638.2005

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Garcia CP, Juliet LC, Fernandez VA, San Martin SM, Cifuentes DM, Porte TL, Braun JS, Castillo DL, Vechiola HM, Tapia PC, Sakurada ZA, Chanqueo CL, Lam EM, Espinoza PM, Curcio FD (2009) Multicenter study on the monitoring of in vitro susceptibility to tigeeyeline in Santiago, Chile. Rev Chilena Infectol 26(3):220–226. doi:/S0716-10182009000400003

    Google Scholar 

  • Garza-Gonzalez E, Llaca-Diaz JM, Bosques-Padilla FJ, Gonzalez GM (2010) Prevalence of multidrug-resistant bacteria at a tertiary-care teaching hospital in Mexico: special focus on Acinetobacter baumannii. Chemotherapy 56(4):275–279. doi:10.1159/000319903

    Article  CAS  PubMed  Google Scholar 

  • Gordon NC, Wareham DW (2009) A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 63(4):775–780. doi:10.1093/jac/dkn555

    Article  CAS  PubMed  Google Scholar 

  • Grandesso S, Sapino B, Amici G, Mazzucato S, Solinas M, Gion M (2014) Are E-test and Vitek2 good choices for tigecycline susceptibility testing when comparing broth microdilution for MDR and XDR Acinetobacter baumannii? New Microbiol 37(4):503–508

    CAS  PubMed  Google Scholar 

  • Guven T, Yilmaz G, Guner HR, Kaya Kalem A, Eser F, Tasyaran MA (2014) Increasing resistance of nosocomial Acinetobacter baumannii: are we going to be defeated? Turk J Med Sci 44(1):73–78

    Article  PubMed  Google Scholar 

  • Higgins PG, Wisplinghoff H, Krut O, Seifert H (2007) A PCR-based method to differentiate between Acinetobacter baumannii and Acinetobacter genomic species 13TU. Clin Microbiol Infect 13(12): 1199–1201. doi:10.1111/j.1469-0691.2007.01819.x

    Article  CAS  PubMed  Google Scholar 

  • Higgins PG, Schneiders T, Hamprecht A, Seifert H (2010) In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. Antimicrob Agents Chemother 54(12):5021–5027. doi:10.1128/AAC.00598-10

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hope R, Warner M, Mushtaq S, Ward ME, Parsons T, Livermore DM (2005) Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines. J Antimicrob Chemother 56(6):1042–1046. doi:10.1093/jac/dki386

    Article  CAS  PubMed  Google Scholar 

  • Hornsey M, Ellington MJ, Doumith M, Thomas CP, Gordon NC, Wareham DW, Quinn J, Lolans K, Livermore DM, Woodford N (2010) AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii. J Antimicrob Chemother 65(8):1589–1593. doi:10.1093/jac/dkq218

    Article  CAS  PubMed  Google Scholar 

  • Hornsey M, Loman N, Wareham DW, Ellington MJ, Pallen MJ, Turton JF, Underwood A, Gaulton T, Thomas CP, Doumith M, Livermore DM, Woodford N (2011) Whole-genome comparison of two Acinetobacter baumannii isolates from a single patient, where resistance developed during tigecycline therapy. J Antimicrob Chemother 66(7):1499–1503. doi:10.1093/jac/dkr168

    Article  CAS  PubMed  Google Scholar 

  • Hua X, Zhou H, Jiang Y, Feng Y, Chen Q, Ruan Z, Yu Y (2012) Genome sequences of two multidrug-resistant Acinetobacter baumannii strains isolated from a patient before and after treatment with tigecycline. J Bacteriol 194(24):6979–6980. doi:10.1128/JB.01887-12

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Insa R, Cercenado E, Goyanes MJ, Morente A, Bouza E (2007) In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia. J Antimicrob Chemother 59(3):583–585. doi:10.1093/jac/dkl496

    Article  CAS  PubMed  Google Scholar 

  • Jiang M, Zhang Z, Zhao S (2014) Epidemiological characteristics and drug resistance analysis of multidrug-resistant Acinetobacter baumannii in a China hospital at a certain time. Pol J Microbiol/Polskie Towarzystwo Mikrobiologow = The Polish Society of Microbiologists 63(3):275–281

    Google Scholar 

  • Jones RN, Ferraro MJ, Reller LB, Schreckenberger PC, Swenson JM, Sader HS (2007) Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol 45(1):227–230. doi:10.1128/JCM.01588-06

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME (2008) Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 62(1):45–55. doi:10.1093/jac/dkn165

    Article  CAS  PubMed  Google Scholar 

  • Kim CK, Lee Y, Lee H, Woo GJ, Song W, Kim MN, Lee WG, Jeong SH, Lee K, Chong Y (2010) Prevalence and diversity of carbapenemases among imipenem-nonsusceptible Acinetobacter isolates in Korea: emergence of a novel OXA-182. Diagn Microbiol Infect Dis 68(4):432–438. doi:10.1016/j.diagmicrobio.2010.07.014

    Article  CAS  PubMed  Google Scholar 

  • Kulah C, Celebi G, Aktas E, Mengeloglu Z, Comert F, Ankarali H (2009) Unexpected tigecycline resistance among Acinetobacter baumannii Isolates: high minor error rate by Etest. J Chemother 21(4):390–395. doi:10.1179/joc.2009.21.4.390

    Article  CAS  PubMed  Google Scholar 

  • Leal Castro AL, Buitrago Gutierrez G, Ovalle V, Cortes JA, Alvarez CA, Colombian Tigecycline Susceptibility Surveillance G (2010) Comparing in vitro activity of tigecycline by using the disk diffusion test, the manual microdilution method, and the VITEK 2 automated system. Rev Argent Microbiol 42(3):208–211

    CAS  PubMed  Google Scholar 

  • Lee YT, Tsao SM, Hsueh PR (2013) Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections. Eur J Clin Microbiol Infect Dis 32(9):1211–1220. doi:10.1007/s10096-013-1870-4

    Article  CAS  PubMed  Google Scholar 

  • Li X, Liu L, Ji J, Chen Q, Hua X, Jiang Y, Feng Y, Yu Y (2015) Tigecycline resistance in Acinetobacter baumannii mediated by frameshift mutation in plsC, encoding 1-acyl-sn-glycerol-3-phosphate acyltransferase. Eur J Clin Microbiol Infect Dis 34(3):625–631. doi:10.1007/s10096-014-2272-y

    Article  CAS  PubMed  Google Scholar 

  • Liao CH, Kung HC, Hsu GJ, Lu PL, Liu YC, Chen CM, Lee CM, Sun W, Jang TN, Chiang PC, Cheng YJ, Lin HC, Shi ZY, Wang LS, Chuang YC, Tsao SM, Lu CT, Liu JW, Huang CH, Hsueh PR (2008) In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan determined by the broth microdilution and disk diffusion methods. Int J Antimicrob Agents 32(Suppl 3):S192–S196. doi:10.1016/S0924-8579(08)70027-X

    Article  CAS  PubMed  Google Scholar 

  • Lin MF, Lan CY (2014) Antimicrobial resistance in Acinetobacter baumannii: from bench to bedside. World J Clin Cases 2(12):787–814. doi:10.12998/wjcc.v2.i12.787

    Article  PubMed  PubMed Central  Google Scholar 

  • Lin MF, Lin YY, Yeh HW, Lan CY (2014) Role of the BaeSR two-component system in the regulation of Acinetobacter baumannii adeAB genes and its correlation with tigecycline susceptibility. BMC Microbiol 14:119. doi:10.1186/1471-2180-14-119

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Liu JW, Wang LS, Cheng YJ, Hsu GJ, Lu PL, Liu YC, Chen CM, Lee CM, Sun W, Jang TN, Chiang PC, Chuang YC, Lin HC, Shi ZY, Kung HC, Huang CH, Tsao SM, Lu CT, Liao CH, Hsueh PR (2008) In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan. Int J Antimicrob Agents 32(Suppl 3):S188–S191. doi:10.1016/S0924-8579(08)70026-8

    Article  CAS  PubMed  Google Scholar 

  • Magnet S, Courvalin P, Lambert T (2001) Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob Agents Chemother 45(12):3375–3380. doi:10.1128/AAC.45.12.3375-3380.2001

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Marchand I, Damier-Piolle L, Courvalin P, Lambert T (2004) Expression of the RND-type efflux pump AdeABC in Acinetobacter baumannii is regulated by the AdeRS two-component system. Antimicrob Agents Chemother 48(9):3298–3304. doi:10.1128/AAC.48.9.3298-3304.2004

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mendes RE, Farrell DJ, Sader HS, Jones RN (2010) Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005–2009). Diagn Microbiol Infect Dis 68(3): 307–311. doi:10.1016/j.diagmicrobio.2010.07.003

    Article  CAS  PubMed  Google Scholar 

  • Moore IF, Hughes DW, Wright GD (2005) Tigecycline is modified by the flavin-dependent monooxygenase TetX. Biochemistry 44(35):11829–11835. doi:10.1021/bi0506066

    Article  CAS  PubMed  Google Scholar 

  • Navon-Venezia S, Leavitt A, Carmeli Y (2007) High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 59(4):772–774. doi:10.1093/jac/dkm018

    Article  CAS  PubMed  Google Scholar 

  • Nemec A, Krizova L, Maixnerova M, van der Reijden TJ, Deschaght P, Passet V, Vaneechoutte M, Brisse S, Dijkshoorn L (2011) Genotypic and phenotypic characterization of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex with the proposal of Acinetobacter pittii sp. nov. (formerly Acinetobacter genomic species 3) and Acinetobacter nosocomialis sp. nov. (formerly Acinetobacter genomic species 13TU). Res Microbiol 162(4):393–404. doi:10.1016/j.resmic.2011.02.006

    Article  CAS  PubMed  Google Scholar 

  • Nigro SJ, Hall RM (2012) Antibiotic resistance islands in A320 (RUH134), the reference strain for Acinetobacter baumannii global clone 2. J Antimicrob Chemother 67(2):335–338. doi:10.1093/jac/dkr447

    Article  CAS  PubMed  Google Scholar 

  • Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C, Llanos AC, Pachon J (2004) Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother 48(11):4479–4481. doi:10.1128/AAC.48.11.4479-4481.2004

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Papaparaskevas J, Tzouvelekis LS, Tsakris A, Pittaras TE, Legakis NJ, Hellenic Tigecycline Study Group (2010) In vitro activity of tigecycline against 2423 clinical isolates and comparison of the available interpretation breakpoints. Diagn Microbiol Infect Dis 66(2):187–194. doi:10.1016/j.diagmicrobio.2009.09.012

    Article  CAS  PubMed  Google Scholar 

  • Paulsen IT (2003) Multidrug efflux pumps and resistance: regulation and evolution. Curr Opin Microbiol 6(5): 446–451. PMID: 14572535

    Google Scholar 

  • Peleg AY, Adams J, Paterson DL (2007) Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother 51(6):2065–2069. doi:10.1128/AAC.01198-06

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT (1999) In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 43(4):738–744

    CAS  PubMed  PubMed Central  Google Scholar 

  • Piewngam P, Kiratisin P (2014) Comparative assessment of antimicrobial susceptibility testing for tigecycline and colistin against Acinetobacter baumannii clinical isolates, including multidrug-resistant isolates. Int J Antimicrob Agents 44(5):396–401. doi:10.1016/j.ijantimicag.2014.06.014

    Article  CAS  PubMed  Google Scholar 

  • Pillar CM, Draghi DC, Dowzicky MJ, Sahm DF (2008) In vitro activity of tigecycline against gram-positive and gram-negative pathogens as evaluated by broth microdilution and Etest. J Clin Microbiol 46(9):2862–2867. doi:10.1128/JCM.00637-08

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ricciardi R, Ricciardi AM, Danzi G (2009) In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii clinical isolates. Le infezioni in medicina: rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 17(4):236–239

    Google Scholar 

  • Rizek C, Ferraz JR, van der Heijden IM, Giudice M, Mostachio AK, Paez J, Carrilho C, Levin AS, Costa SF (2015) In vitro activity of potential old and new drugs against multidrug-resistant gram-negatives. J Infect Chemother 21(2):114–117. doi:10.1016/j.jiac.2014.10.009

    Article  CAS  PubMed  Google Scholar 

  • Rosenfeld N, Bouchier C, Courvalin P, Perichon B (2012) Expression of the resistance-nodulation-cell division pump AdeIJK in Acinetobacter baumannii is regulated by AdeN, a TetR-type regulator. Antimicrob Agents Chemother 56(5):2504–2510. doi:10.1128/AAC.06422-11

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rumbo C, Gato E, Lopez M, Ruiz de Alegria C, Fernandez-Cuenca F, Martinez-Martinez L, Vila J, Pachon J, Cisneros JM, Rodriguez-Bano J, Pascual A, Bou G, Tomas M, Spanish Group of Nosocomial I, Mechanisms of A, Resistance to A, Spanish Society of Clinical M, Infectious D, Spanish Network for Research in Infectious D (2013) Contribution of efflux pumps, porins, and beta-lactamases to multidrug resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 57(11):5247–5257. doi:10.1128/AAC.00730-13

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ruzin A, Keeney D, Bradford PA (2007) AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J Antimicrob Chemother 59(5):1001–1004. doi:10.1093/jac/dkm058

    Article  CAS  PubMed  Google Scholar 

  • Ruzin A, Immermann FW, Bradford PA (2010) RT-PCR and statistical analyses of adeABC expression in clinical isolates of Acinetobacter calcoaceticus-Acinetobacter baumannii complex. Microb Drug Resist 16(2):87–89. doi:10.1089/mdr.2009.0131

    Article  CAS  PubMed  Google Scholar 

  • Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritsche TR (2005) Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis 52(3):181–186. doi:10.1016/j.diagmicrobio.2005.05.005

    Article  CAS  PubMed  Google Scholar 

  • Sader HS, Farrell DJ, Flamm RK, Jones RN (2014) Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012). Antimicrob Agents Chemother 58(4):2274–2280. doi:10.1128/AAC.02684-13

    Article  PubMed  PubMed Central  Google Scholar 

  • Scheetz MH, Qi C, Warren JR, Postelnick MJ, Zembower T, Obias A, Noskin GA (2007) In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob Agents Chemother 51(5):1621–1626. doi:10.1128/AAC.01099-06

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Seifert H, Stefanik D, Wisplinghoff H (2006) Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolates. J Antimicrob Chemother 58(5):1099–1100. doi:10.1093/jac/dkl383

    Article  CAS  PubMed  Google Scholar 

  • Spiliopoulou A, Jelastopulu E, Vamvakopoulou S, Bartzavali C, Kolonitsiou F, Anastassiou ED, Christofidou M (2014) In vitro activity of tigecycline and colistin against A. baumannii clinical bloodstream isolates during an 8-year period. J Chemother. doi:10.1179/1973947814Y.0000000193

  • Srinivasan VB, Vaidyanathan V, Rajamohan G (2015) AbuO, a TolC-like outer membrane protein of Acinetobacter baumannii, is involved in antimicrobial and oxidative stress resistance. Antimicrob Agents Chemother 59(2):1236–1245. doi:10.1128/AAC.03626-14

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Stein GE, Babinchak T (2013) Tigecycline: an update. Diagn Microbiol Infect Dis 75(4):331–336. doi:10.1016/j.diagmicrobio.2012.12.004

    Article  CAS  PubMed  Google Scholar 

  • Sun JR, Chan MC, Chang TY, Wang WY, Chiueh TS (2010) Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS. Antimicrob Agents Chemother 54(11):4934–4938. doi:10.1128/AAC.00414-10

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sun JR, Perng CL, Chan MC, Morita Y, Lin JC, Su CM, Wang WY, Chang TY, Chiueh TS (2012) A truncated AdeS kinase protein generated by ISAba1 insertion correlates with tigecycline resistance in Acinetobacter baumannii. PLoS One 7(11):e49534. doi:10.1371/journal.pone.0049534

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sun Y, Cai Y, Liu X, Bai N, Liang B, Wang R (2013) The emergence of clinical resistance to tigecycline. Int J Antimicrob Agents 41(2):110–116. doi:10.1016/j.ijantimicag.2012.09.005

    Article  CAS  PubMed  Google Scholar 

  • Sun JR, Perng CL, Lin JC, Yang YS, Chan MC, Chang TY, Lin FM, Chiueh TS (2014) AdeRS combination codes differentiate the response to efflux pump inhibitors in tigecycline-resistant isolates of extensively drug-resistant Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis 33(12):2141–2147. doi:10.1007/s10096-014-2179-7

    Article  CAS  PubMed  Google Scholar 

  • Tan TY, Ng LS (2007) Susceptibility of multi-resistant Gram-negative bacilli in Singapore to tigecycline as tested by agar dilution. Ann Acad Med Singap 36(10):807–810. PMID: 17987230

    Google Scholar 

  • Taneja N, Singh G, Singh M, Sharma M (2011) Emergence of tigecycline & colistin resistant Acinetobacter baumanii in patients with complicated urinary tract infections in north India. Indian J Med Res 133:681–684

    CAS  PubMed  PubMed Central  Google Scholar 

  • Teng SO, Yen MY, Ou TY, Chen FL, Yu FL, Lee WS (2014) Comparison of pneumonia- and non-pneumonia-related Acinetobacter baumannii bacteremia: impact on empiric therapy and antibiotic resistance. J Microbiol Immunol Infect = Wei mian yu gan ran za zhi. doi:10.1016/j.jmii.2014.06.011

  • Thamlikitkul V, Tiengrim S (2008) Effect of different Mueller-Hinton agars on tigecycline disc diffusion susceptibility for Acinetobacter spp. J Antimicrob Chemother 62(4):847–848. doi:10.1093/jac/dkn267

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Thamlikitkul V, Tiengrim S, Tribuddharat C (2007) Comment on: high tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 60(1):177–178. doi:10.1093/jac/dkm142

  • Towner KJ (2009) Acinetobacter: an old friend, but a new enemy. J Hosp Infect 73(4):355–363. doi:10.1016/j.jhin.2009.03.032

    Article  CAS  PubMed  Google Scholar 

  • Van TD, Dinh QD, Vu PD, Nguyen TV, Pham CV, Dao TT, Phung CD, Hoang HT, Tang NT, Do NT, Nguyen KV, Wertheim H (2014) Antibiotic susceptibility and molecular epidemiology of complex strains isolated from a referral hospital in northern Vietnam. J Glob Antimicrob Resist 2(4):318–321. doi:10.1016/j.jgar.2014.05.003

    Article  PubMed  PubMed Central  Google Scholar 

  • Yahav D, Lador A, Paul M, Leibovici L (2011) Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 66(9): 1963–1971. doi:10.1093/jac/dkr242

    Article  CAS  PubMed  Google Scholar 

  • Yoon EJ, Courvalin P, Grillot-Courvalin C (2013) RND-type efflux pumps in multidrug-resistant clinical isolates of Acinetobacter baumannii: major role for AdeABC overexpression and AdeRS mutations. Antimicrob Agents Chemother 57(7):2989–2995. doi:10.1128/AAC.02556-12

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zarate MS, Serruto G, Smayevsky J (2010) The susceptibility to tigecycline of Acinetobacter spp. may vary depending on the methodology used. Int J Infect Dis 14(Suppl 3):e351–e352. doi:10.1016/j.ijid.2009.08.015

    Article  PubMed  Google Scholar 

  • Zarkotou O, Pournaras S, Altouvas G, Pitiriga V, Tziraki M, Mamali V, Themeli-Digalaki K, Tsakris A (2012) Comparative evaluation of tigecycline susceptibility testing methods for expanded-spectrum cephalosporin- and carbapenem-resistant gram-negative pathogens. J Clin Microbiol 50(11):3747–3750. doi:10.1128/JCM.02037-12

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

No institutional and/or corporate funds have been received by authors for the achievement of the results reported in the manuscript.

Author information

Authors and Affiliations

  1. Department of Microbiology, Medical School, University of Athens, Athens, 11527, Greece

    Spyros Pournaras, Vasiliki Koumaki, Vasiliki Gennimata & Athanassios Tsakris

  2. Department of Biopathology, Aretaieio Hospital, University of Athens, Athens, Greece

    Spyros Pournaras & Evangelia Kouskouni

Authors
  1. Spyros Pournaras
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vasiliki Koumaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vasiliki Gennimata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Evangelia Kouskouni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Athanassios Tsakris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Athanassios Tsakris .

Editor information

Editors and Affiliations

  1. Microbial Biofilm Laboratory, Fondazione Santa Lucia IRCCS, Rome, Italy

    Gianfranco Donelli

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Pournaras, S., Koumaki, V., Gennimata, V., Kouskouni, E., Tsakris, A. (2015). In Vitro Activity of Tigecycline Against Acinetobacter baumannii: Global Epidemiology and Resistance Mechanisms. In: Donelli, G. (eds) Advances in Microbiology, Infectious Diseases and Public Health. Advances in Experimental Medicine and Biology(), vol 897. Springer, Cham. https://doi.org/10.1007/5584_2015_5001

Download citation

Publish with us

Policies and ethics

Search

Navigation